第11批药品集采结果公布，医药板块持续活跃

Group 1 - The 11th batch of national organized drug procurement results has been officially announced, set to be implemented in February 2026 [1] - A total of 55 drugs have been included in this procurement, covering commonly used medications in areas such as anti-infection, anti-allergy, anti-tumor, blood sugar reduction, blood pressure reduction, blood lipid reduction, and anti-inflammatory pain relief [1] - The average price difference for selected drugs in this procurement has narrowed to 1.7 times, with 8 varieties initiating a price correction mechanism to maintain normal pricing order [1] Group 2 - During the 14th Five-Year Plan period, China has approved 210 innovative drugs and 269 innovative medical devices, both showing accelerated growth [1] - China's biopharmaceutical market has become the second largest globally, with approximately 30% of global innovative drugs under research [1] - In the first half of 2025, the total amount of innovative drug licensing agreements reached nearly $66 billion, indicating increasing global recognition of Chinese innovative drugs [1] Group 3 - As of November 12, 2025, the three major A-share indices collectively adjusted, with the Shanghai Composite Index down 0.14%, Shenzhen Component Index down 0.62%, and ChiNext Index down 0.81% [2] - The Kexin Pharmaceutical ETF (588130) rose by 1.22%, with the latest quote at 1.164 yuan and a turnover rate of 7.36% [2] - Among component stocks, Hejing Biological led with an increase of 8.23%, while several other stocks showed mixed performance [2]